Related Experiment Video
Updated: Aug 9, 2026

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation
Published on: November 3, 2018
Preleukaemia and myelodysplastic syndromes today
Abstract:
The clinical picture of myelodysplastic syndromes (MDS) results from the expansion of an abnormal clone of haemopoietic stem cells that has undergone premalignant transformation. Different types of "oncogene" may be involved in this process, some of which code for growth factors and their receptors, some for membrane or cytoplasmic proteins and some for nuclear binding proteins. The insults causing gene mutations are not known, though chemical, viral or radiation damage could be important. The most striking feature of MDS is the inadequate production of dysplastic, poorly functional cells as a result of impaired differentiation and premature cell death in the bone marrow. Treatment is currently directed to supportive therapy with blood components and antibiotics, attempts to stimulate proliferation and differentiation with recombinant human growth factors, and, in a few cases, bone marrow transplantation. Chemotherapy alone has met with little success.
Related Concept Videos
Abnormal Proliferation
Lineage Commitment
Differentiation of Common Myeloid Progenitor Cells
Disorders of Leukocytes
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Cellular Adaptation IV: Dysplasia and Metaplasia

